Kevin Puylaert is Chief Sales Officer at SOPHiA GENETICS SA (SOPH). They have made 7 open-market trades across 1 company since 2026, most recently 2026-10-05.
CIK 0002119354
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SOPH | 147,732 | $957K |
Shares reported on the most recent Form 4, priced at the 2026-10-07 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SOPH | SELL | 2026-10-05 | 2026-10-07 | $8.04 | $2K | -7.2% | — | — |
| SOPH | SELL | 2026-07-06 | 2026-07-07 | $5.03 | $1K | +8.2% | +22.9% | +51.0% |
| SOPH | SELL | 2026-05-19 | 2026-05-20 | $4.54 | $150 | +0.6% | +10.0% | +56.0% |
| SOPH | SELL | 2026-04-20 | 2026-04-21 | $5.08 | $168 | +1.2% | -2.5% | +22.8% |
| SOPH | SELL | 2026-04-06 | 2026-04-08 | $4.86 | $3K | +8.1% | +7.9% | +13.3% |
| SOPH | SELL | 2026-03-31 | 2026-04-01 | $4.71 | $14 | -1.8% | +3.6% | +14.2% |
| SOPH | SELL | 2026-03-19 | 2026-03-20 | $4.76 | $157 | +3.5% | +5.5% | +11.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.